Clarivate Appoints New Director, J.P. Garnier
Ticker: CLVT · Form: 8-K · Filed: Feb 28, 2025 · CIK: 1764046
Sentiment: neutral
Topics: board-appointment, governance
Related Tickers: CLVT
TL;DR
Clarivate adds J.P. Garnier, ex-GSK CEO, to its board.
AI Summary
Clarivate Plc announced on February 28, 2025, that its Board of Directors has appointed Dr. J.P. Garnier as a Class II Director, effective February 25, 2025. Dr. Garnier will serve until the company's 2027 annual general meeting and will be a member of the Audit Committee and the Nominating and Corporate Governance Committee. He previously served as CEO of GlaxoSmithKline plc.
Why It Matters
The appointment of a new director with significant industry experience can signal strategic shifts or enhanced governance for the company.
Risk Assessment
Risk Level: low — The filing is a routine corporate announcement regarding board appointments and does not involve significant financial transactions or operational changes.
Key Players & Entities
- Clarivate Plc (company) — Registrant
- J.P. Garnier (person) — Appointed Director
- GlaxoSmithKline plc (company) — Former Employer of Appointed Director
- February 25, 2025 (date) — Effective date of appointment
- 2027 (date) — Term end year for the director
FAQ
Who has been appointed as a new director to the Clarivate Plc Board?
Dr. J.P. Garnier has been appointed as a Class II Director.
When is Dr. J.P. Garnier's appointment effective?
The appointment is effective as of February 25, 2025.
Until when will Dr. J.P. Garnier serve as a director?
Dr. Garnier will serve until the company's 2027 annual general meeting.
Which committees will Dr. J.P. Garnier be a member of?
Dr. Garnier will be a member of the Audit Committee and the Nominating and Corporate Governance Committee.
What was Dr. J.P. Garnier's previous executive role?
Dr. Garnier previously served as CEO of GlaxoSmithKline plc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 28, 2025 by J.P. Garnier regarding CLARIVATE PLC (CLVT).